Form 4: Dynavax Director Francis Cano Boosts Stake with Equity Grants

Dynavax Technologies Corp. Director Francis Cano has increased his beneficial ownership through the acquisition of 5,758 restricted stock units and 28,500 stock options, as reported in a recent SEC Form 4 filing.

Summary

• Francis Cano, a Director of Dynavax Technologies Corp. (DVAX), acquired 5,758 shares of Common Stock in the form of Restricted Stock Units (RSUs) on June 11, 2025.
• These RSUs were acquired at a price of $0, indicating they are part of compensation or a grant.
• Following this transaction, Mr. Cano's direct beneficial ownership of Common Stock is 42,663 shares.
• Mr. Cano also acquired 28,500 stock options with an exercise price of $10.18 per share on June 11, 2025.
• These stock options have an expiration date of June 10, 2032.
• Both the RSUs and stock options are subject to a one-year vesting period from the grant date (June 11, 2025), contingent on Mr. Cano's continued service to the company.
• The release of RSU shares will be mandatorily deferred six months and one day after Mr. Cano no longer provides services to the Company.

Sentiment

Score: 7

Explanation: The acquisition of equity by a director, particularly through compensation grants, is generally viewed positively as it aligns the director's interests with shareholders and signals confidence in the company's future.

Positives

• Director Francis Cano's acquisition of additional equity (RSUs and stock options) aligns his interests with shareholders, demonstrating confidence in the company's future performance.
• The grant of stock options with an exercise price of $10.18 provides an incentive for the director to contribute to the company's stock price appreciation.

Risks

• The vesting of RSUs and stock options is contingent on continued service, meaning the benefits are not immediate and depend on the director's ongoing employment with the company.

Future Outlook

The equity grants to Director Francis Cano, structured with a one-year vesting period, align his future compensation with the company's performance, incentivizing long-term value creation and retention.

Industry Context

The grant of restricted stock units and stock options to a director is a common practice in the biotechnology and pharmaceutical industries, serving as a key component of executive compensation packages designed to align the interests of leadership with long-term shareholder value creation. This type of equity-based compensation is prevalent across the sector, aiming to incentivize performance and retention.

Comparison to Industry Standards

• The structure of equity grants, including RSUs and stock options with vesting periods tied to continued service, is consistent with compensation practices observed in comparable biotechnology companies.
• While specific grant sizes vary based on company size, executive role, and performance metrics, the use of such instruments is a global benchmark for aligning director incentives with company growth and shareholder returns.

Stakeholder Impact

• Shareholders: Potentially positive, as the director's increased equity stake aligns his financial interests directly with the company's stock performance and long-term value creation.

Next Steps

• The RSUs and stock options will vest one year from the grant date (June 11, 2025), contingent on continued service.
• The stock options will expire on June 10, 2032, if not exercised.
• The release of RSU shares will be mandatorily deferred six months and one day after the reporting person no longer provides services to the company.

Key Dates

Keywords

DVAX, Dynavax Technologies, Francis Cano, SEC Form 4, Insider Transaction, Restricted Stock Units, Stock Options, Director Compensation, Equity Grant